The Relationship Between Level of Transforming Growth Factor - β with Pulmonary Fibrosis in Post Pulmonary Tuberculosis in Medan

Tamara Christine, Amira Permatasari Tarigan, Nuryunita Nainggolan, Fotarisman Zaluchu


Background: Untreated or undertreated, pulmonary tuberculosis could cause severe complications until death. After treatment, residual lesions might occur. The presence of residual lesions is varied, including: fibrosis, cavity, bronchiectasis and calcification. Transforming growth factor-β (TGF-β) is a cytokine associated with lung inflammation, which plays a role in lung fibrosis. However, only a few studies have assessed the serum level of TGF-β in post-treatment tuberculosis patients. The main objective of this study was to determine the relationship between TGF-β levels and pulmonary fibrosis in patients with pulmonary tuberculosis.
Methods: Among 51 patients that had undergone anti-tuberculosis treatment were observed, consisting of 31 men, 20 women. Of all patients, there were 26 people with a smoking history, including 25 men and 1 woman. All patients had been recovered, confirmed by clinical state, laboratory and radiology examination. The ELISA test was performed to measure TGF-β level, while chest X-ray was used to evaluate for the occurence of pulmonary fibrosis.
Results: The mean level of TGF-β in patients with lesion (+) was 7628.02 pg/mL (SD: ±4928.38) while the mean level of TGF-β in patients with lesion (-) was 2315.11 pg/mL (SD: ±505.83). Statistical test showed a significant relationship between TGF-β level and fibrosis lesion (P<0.001).
Conclusions: TGF-β level was significantly higher in post-tuberculosis patients with pulmonary fibrosis. (J Respir Indo. 2020; 40(1): 1-5)


TGF-β, post-pulmonary tuberculosis, lung fibrosis

Full Text:



Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Pedoman Nasional Pengendalian Tuberkulosis: Indonesia Bebas Tuberkulosis. Jakarta. 2014.

World Health Organization (WHO). Global Tuberculosis Report. Geneva. 2016.

Tarigan AP, Pandia P, Eyanoer P, Tina D, Pratama R, Fresia A, et al. Obstructive lung disease as a complication in post pulmonary TB. IOP Conf. Ser.: Earth Environ Sci. 2018;125(1):012154.

Tambunan DTR, Tarigan AP, Sinaga B, Pandia P, Eyanoer PC. Correlaton of serum tumor necrosis factor-alpha level with pulmonary function in post pulmonary tuberculosis patients. Respirology. 2017;22:218.

Harada S, Harada Y, Kitara Y, Takamoto M, Ishibashi T, Shinoda A. Tuberculosis sequelae: clinical aspects. Kekkaku. 1990;65(12):831-8.

Kim HY, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic sequelae and complication of tuberculosis. Radiographics. 2001;21(4):839-60.

Branton MH, Kopp JB. TGF-β and fibrosis. Microbes Infect. 1999;1(15):1349-65.

Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J. 2004; 18(7):816-27.

McCartney-Francis N, Mizel D, Wong H, Wahl L, Wahl S. TGF-β regulates production of growth factors and TGF-β by human peripheral blood monocytes. Growth Factors. 1990;4(1):27–35.

Deveci F, Akbulut HH, Turgut T, Muz MH. Changes in serum cytokine levels in active tuberculosis with treatment. Mediators Inflamm. 2005;2005(5):256–62.

Achanta S, Tekumalla RR, Jaju J, Purad C, Chepuri R, Samyukta R, Malhotra S, nagaraja SB, Kumar AM, Harries AD. Screening tuberculosis patients for diabetes in a tribal area in South India. Public Health Action. 2013;3(Suppl 1):44S43-7.

Chung KP, Chen JY, Lee CH, Wu WD, Wang JY, Lee LN, et al. Trends and predictors changes in pulmonary function after treatment for pulmonry tuberculosis. Clinics (Sao Paulo). 2011;66(4):549-55.

Manji M, Shayo G, Mamuya S, Mpembeni R, Jusabani A, Mugusi F. Lung function among patients with pulmonary tuberculosis in Dar es Salaam - a cross-sectional study. BMC Pulm Med. 2016;16:58.

Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia, 2016.

Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar, Riskesdas 2013. Jakarta: Kementerian Kesehatan Republik Indonesia, 2013.

Menon B, Nima G, Dogra V, Jha S. Evaluation of the radiological sequelae after treatment completion in new cases of pulmonary, pleural and mediastinal tuberculosis. Lung India. 2015;32(3):241-5.

Assoian RK, Fleurdelys BE, Stevensin HC, Miller PJ, Madtes DK, Raines EW, et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Pro Natl Acad Sci USA. 1987;84(17):6020-4.

Blakytny R, Ludlow A, Martin GE, Ireland G, Lund LR, Ferguson MW, et al. Latent TGF-β1 activation by platelets. J Cell Physiol. 2004;199(1):67–76.

Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9(3):111-6.

Gerarduzzi C, Di Battista JA. Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective. Inflamm Res. 2017;66(6):451-65.

Martin GEM, Ask K, Gilpin SE, Kolb M, Gauldie J. The transforming growth factor-beta (TGF-β) family and pulmonary fibrosis. Respiratory diseases. 2006;3(1):99-103.

Massague´ J. Receptors for the TGF-β family. Cell. 1992;69(7):1067–70.

Laurent GJ, McAnulty RJ, Hill M, Chambers R. Escape from matrix, multiple mechanism for fibroblast activation in pulmonary fibrosis. Proc Am Thorac Soc. 2008;5(3):311-5.

Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. Latent TGF-β structure and activation. Nature. 2011;474(7351):343-9.



  • There are currently no refbacks.

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License